Granules India Limited (NSE:GRANULES)
600.95
+2.55 (0.43%)
Dec 31, 2025, 3:30 PM IST
Granules India Revenue
Granules India had revenue of 12.97B INR in the quarter ending September 30, 2025, with 34.18% growth. This brings the company's revenue in the last twelve months to 48.42B, up 8.14% year-over-year. In the fiscal year ending March 31, 2025, Granules India had annual revenue of 44.82B, down -0.55%.
Revenue (ttm)
48.42B
Revenue Growth
+8.14%
P/S Ratio
3.00
Revenue / Employee
11.91M
Employees
4,066
Market Cap
145.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Granules India News
- 8 days ago - Granules India board approves fundraise of upto Rs 1,462 crore via issue of warrants at Rs 585 - Business Upturn
- 9 days ago - Granules India subsidiary receives FDA Tentative Approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets - Business Upturn
- 12 days ago - Granules India subsidiary completes USFDA inspection with five procedural observations - Business Upturn
- 12 days ago - Granules India subsidiary receives five procedural observations after US FDA GMP inspection - Business Upturn
- 19 days ago - Granules India subsidiary secures FDA EIR for Hyderabad Facility - Business Upturn
- 27 days ago - Granules packaging unit clears USFDA inspection - The Times of India
- 27 days ago - Granules India’s US Packaging Facility Clears FDA Inspection With Zero Observations - Business Upturn
- 4 weeks ago - Granules India sets up 2 advanced R&D CoEs at IITH - The Times of India